A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate‐to‐severe plaque‐type psoriasis patients treated with infliximab in routine care settings of Greece

Petridis, Athanasios K.; Panagakis, Pantelis; Moustou, E; Vergou, Theognosia; Kallidis, P.; Mandekou‐Lefaki, Ioanna; Chaidemenos, Georgios; Sotiriadis, Dimitrios; Alexopoulou, G; Haratsis, Y; Antoniou, Christina

doi:10.1111/jdv.14802

Cited by 10 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…38 Super-responders appeared to be healthier than the rest of the patients receiving biologics and only a small proportion of patients had any comorbidities from the Charlson Comorbidity Index, which is in line with previous studies showing that the absence of comorbidities is associated with longer drug survival. 12,33,[39][40][41] Super-responders had lower baseline PASI, in line with previous studies finding low baseline PASI to be associated with higher odds of achieving response based on absolute PASI. 35 The most pronounced difference in characteristics was observed for socioeconomic status, with 64% of patients who were super-responders being in one of the two highest SES groups compared with 38% of the rest of the patients receiving biologics for psoriasis.…”

Section: Discussionsupporting

confidence: 90%

“…Super‐responders appeared to be healthier than the rest of the patients receiving biologics and only a small proportion of patients had any comorbidities from the Charlson Comorbidity Index, which is in line with previous studies showing that the absence of comorbidities is associated with longer drug survival 12,33,39–41 . Super‐responders had lower baseline PASI, in line with previous studies finding low baseline PASI to be associated with higher odds of achieving response based on absolute PASI 35 .…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Prevalence and characterization of treatment‐refractory psoriasis and super‐responders to biologic treatment: a nationwide study

Loft

Egeberg

Rasmussen

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Introduction Treatment with biologics often leads to clearance of psoriasis. However, some patients do repeatedly fail to respond and/or lose an achieved response (treatment refractory) to the biologic, whereas other patients achieve excellent response to one biologic and remain clear of psoriasis for several years (super‐responders). Objective To identify and characterize patients with treatment refractory psoriasis and patients who are super‐responders to biologic treatment. Material and methods Patients registered in DERMBIO between January 2007 and November 2019 were included. Patients were categorized as being treatment refractory if they had had treatment failure to ≥3 biologics targeting ≥2 different pathways. Super‐responders were patients treated with their first biologic for minimum 5 years without an absolute psoriasis area and severity index (PASI) > 3 between 6 months and 5 years of treatment. All remaining patients from DERMBIO served as comparators. Results In total, 3280 patients were included with a mean age of 45.0 years. 1221 (37%) of the patients were females. Of the included patients, 214 (6.5%) were categorized as treatment refractory and 207 (6.3%) were categorized as super‐responders. Treatment refractory patients had higher mean body weight (100.6 kg vs. 90.6 kg, P < 0.0001) and higher mean BMI (32.2 vs. 29.4, P < 0.0001) compared with the rest of patients in DERMBIO. Super‐responders had higher socioeconomic status and fewer comorbidities compared with the comparator group (P < 0.0001). Conclusion A small proportion of patients with psoriasis treated with biologics are either super‐responders or treatment refractory. Treatment refractory patients have higher body weight, whereas super‐responders have fewer comorbidities and higher socioeconomic status.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 87%

Prevalence and characterization of treatment‐refractory psoriasis and super‐responders to biologic treatment: a nationwide study

Loft

Egeberg

Rasmussen

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Petridis et al [45], in a multicentre, prospective, observational study, examined the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings in Greece.…”

Section: Correlation Between Obesity—body Weight and Body Mass Indmentioning

confidence: 99%

Biomarkers of Inflammation in Obesity-Psoriatic Patients

Rodríguez-Cerdeira

Cordeiro-Rodríguez

Carnero-Gregorio

et al. 2019

Mediators of Inflammation

View full text Add to dashboard Cite

Psoriasis is a common chronic inflammatory multisystemic disease with a complex pathogenesis consisting of genetic, immunological, and environmental components. It is associated with a number of comorbidities, including diabetes, metabolic syndrome, obesity, and myocardial infarction. In addition, the severity of psoriasis seems to be related to the severity of obesity. Patients with higher levels of obesity show poorer response to systemic treatments of psoriasis. Several studies have demonstrated that white adipose tissue is a crucial site of the formation of proinflammatory adipokines such as leptin, adiponectin, and resistin and classical cytokines such as interleukin- (IL-) 6 and tumour necrosis factor-α. In psoriasis, due to the proliferation of Th1, Th17, and Th22 cells, IL-22, among others, is produced in addition to the abovementioned cytokines. With respect to leptin and resistin, both of these adipokines are present in high levels in obese persons with psoriasis. Further, the plasma levels of leptin and resistin are related to the severity of psoriasis. These results strongly suggest that obesity, through proinflammatory pathways, is a predisposing factor to the development of psoriasis and that obesity aggravates existing psoriasis. Different inflammatory biomarkers link psoriasis and obesity. In this paper, the most important ones are described.

show abstract

“…In the same way, elevated BMI tended to be associated with PPP. The impact of obesity on PV severity and in biological therapy resistance is well described, [18][19][20] but our study is the first to report in PPP. Given (i) the activation of the T helper 17 (Th17) cell pathway in obesity due to fatty acids and adiponectin, [21][22][23][24] (ii) the association of PPP with overweight, (iii) a reported efficiency of interleukin-17 (IL-17), IL-12/23 and IL-23 inhibitors 6,[25][26][27] in PPP, the Th17 pathway could be involved in PPP development, as previously suggested.…”

Section: Discussionmentioning

confidence: 70%

Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort

Assan

Husson

Hegazy

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Acral pustular disease within the pustular psoriasis/psoriasis‐like spectrum mainly includes palmoplantar pustulosis (PPP) and acrodermatitis continua of Hallopeau (ACH). Scarce data argue for a distinction between these two entities, but no study has compared the clinical and epidemiologic characteristics of ACH and PPP. Objectives We aimed to perform a comparative description of the epidemiological and clinical characteristics of PPP and ACH in a multicentre retrospective cohort. Methods In this multicentre national retrospective cohort study, we compared the epidemiological characteristics, comorbidities and psoriasis characteristics of patients with PPP and ACH. Results A total of 234 patients were included: 203 (87%) with PPP, 18 (8%) with ACH and 13 (6%) with both, according to 2017 ERASPEN criteria. As compared with ACH, PPP was associated with female sex, smoking activity and higher median BMI (P = 0.01, P = 0.02 and P = 0.05 respectively). A family background of psoriasis was more frequent in PPP than ACH. Age of onset of palmoplantar disease was similar between PPP and ACH patients, median age 44 and 48 years respectively. Peripheral joint inflammatory involvement was the only rheumatic disease associated with ACH. The association with another psoriasis type was similar in PPP and ACH (57.6% and 61.1% respectively). Conclusion Our study confirms in a large PPP cohort the predominance of females and a high prevalence of smoking and elevated body mass index but also shows an association of these features in PPP as compared with ACH. In addition, it highlights peripheral arthritis as the only arthritis endotype associated with ACH. Increased knowledge of the immunogenetic backgrounds underlying these two entities is warranted to better stratify pustular psoriasis or psoriasis‐like entities for precision medicine.

show abstract

A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate‐to‐severe plaque‐type psoriasis patients treated with infliximab in routine care settings of Greece

Abstract: In the routine care of Greece, infliximab reduced disease activity and improved the quality of life of moderate-to-severe psoriasis patients through 1 year of treatment, independent of their BMI and WC.

Cited by 10 publications

References 36 publications

Prevalence and characterization of treatment‐refractory psoriasis and super‐responders to biologic treatment: a nationwide study

Prevalence and characterization of treatment‐refractory psoriasis and super‐responders to biologic treatment: a nationwide study

Biomarkers of Inflammation in Obesity-Psoriatic Patients

Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort

Contact Info

Product

Resources

About